Visible light-activatable platinum(iv) prodrugs harnessing CD36 for ovarian cancer therapy

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

May Cheline; Hao Shen; Barry D. Dunietz; Yao-Rong Zheng

doi:10.1039/d3dt01292a

Visible light-activatable platinum(iv) prodrugs harnessing CD36 for ovarian cancer therapy

May Cheline & Yao-Rong Zheng et al. · 2023-08-08

5Citations

Visible light-activatable Pt(iv) prodrugs harness the upregulated CD36 to facilitate cell entry and killing of drug resistant ovarian cancer cells.

Links

DOI PubMed

Journal

Dalton Transactions

TL;DR

Pt(IV) compounds mimic the structure of fatty acids and take advantage of CD36 as a "Trojan horse" to gain entry into the cells, and can be activated to form Pt(II) with characteristics of cisplatin under visible light irradiation.

AI-generated by Semantic Scholar

NCI NIH HHS

R15 CA249712

National Cancer Institute

1R15CA249712-01A1

Visible light-activatable platinum(iv) prodrugs harnessing CD36 for ovarian cancer therapy

Links

Journal

TL;DR

Institutions

Authors

Funding